The European Commission issued a Statement of Objections to Danish pharmaceutical company Lundbeck and four generic groups alleging agreements were made to delay entry of generic versions of citalopram, a widely used antidepressant. Preliminary investigations indicate that Lundbeck conducted “value transfers” to generic competitors in the form of direct payments, guaranteed profits in distribution agreements, and the purchase of generic citalopram stock. In exchange, generic competitors may delay putting a generic citalopram on the market for up to two years to keep brand name prices high. Reuters reports Lundbeck denies the allegations and asserted full compliance with EU competition law.
This investigation is the European Commission’s first case dealing with “pay for delay” agreements.
Full content: The Information Daily Reuters
Related content: Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion Review of Reverse-Payment Agreements: The Agencies, the Courts, Congress, and the European Commission
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI